Cardiotoxicity of the HER2 dimerisation inhibitor pertuzumab in patients with breast cancer HER2+: A systematic review

被引：0
|
作者：
Olivares Hernandez, A. [1 ]
Escala Cornejo, R. A. [2 ]
Toribio Garcia, I. [3 ]
Figuero Perez, L. [4 ]
Vidal Tocino, R. [5 ]
Miramontes Gonzalez, J. P. [6 ]
Martin Garcia, G. [4 ]
Seijas Tamayo, R. [4 ]
Cruz-Hernandez, J. J. [7 ]
Rodriguez Sanchez, C. A. [8 ]
机构：
[1] IBSAL Inst Invest Biomed Salamanca, Dept Med Oncol, Salamanca, Spain
[2] Complejo Asistencial Avila Hosp Nuestra Senora So, Dept Med Oncol, Avila, Spain
[3] Univ Hosp Leon, Cardiol, Leon, Spain
[4] Univ Hosp Salamanca, Med Oncol, Salamanca, Spain
[5] IBSAL Inst Invest Biomed Salamanca, Dept Med Oncol, Salamanca, Spain
[6] Univ Hosp Rio Hortega, Internal Med, Valladolid, Spain
[7] Hosp Clin Univ Salamanca, Med Oncol, Salamanca, Spain
[8] IBSAL Inst Invest Biomed Salamanca, Med Oncol, Salamanca, Spain
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.720
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1832P
引用
收藏
页码：S1240 / S1240
页数：1
相关论文
共 50 条
  • [21] Evaluation of analytical accuracy of HER2 status in patients with breast cancer Comparison of HER2 GPA with HER2 IHC and HER2 FISH
    Jensen, Steffen Grann
    Thomas, Peter Engel
    Christensen, Ib Jarle
    Balslev, Eva
    Hansen, Alastair
    Hogdall, Estrid
    [J]. APMIS, 2020, 128 (11) : 573 - 582
  • [22] TRASTUZUMAB EMTANSINE FOR HER2 POSITIVE BREAST CANCER PATIENTS: AN UPDATED SYSTEMATIC REVIEW
    Valle, P. M.
    Mosegui, G. B.
    Vianna, C. M.
    Araujo, R. L.
    Felicissimo, T.
    Lima, I. J.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A816 - A816
  • [23] Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)
    Moulder, Stacy L.
    Borges, Virginia F.
    Baetz, Tara
    Mcspadden, Tessa
    Fernetich, Gina
    Murthy, Rashmi K.
    Chavira, Renae
    Guthrie, Kari
    Barrett, Emma
    Chia, Stephen K.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (14) : 3529 - 3536
  • [24] ADDING PERTUZUMAB IN NEOADJUVANT TREATMENT OF PATIENTS WITH HER2+ BREAST CANCER IN SPAIN: A COST OFFSETS STUDY
    Albanell, J.
    Ciruelos, E.
    Colomer, R.
    De la Haba, J.
    Martin, M.
    De Salas-Cansado, M.
    Munoz-Molina, B.
    Tournier, C.
    Thuresson, P.
    Schleich, W.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2015, 117 : 42 - 42
  • [25] HER2 testing in patients with breast cancer
    Dixon, J. Michael
    Wilson, Victoria
    Verrill, Mark
    Symmans, W. Fraser
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2012, 344
  • [26] Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment
    Alessio Di Luca
    Michael Henry
    Paula Meleady
    Robert O’Connor
    [J]. DARU Journal of Pharmaceutical Sciences, 23
  • [27] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Chen, Zhaoxu
    Jia, Huiqing
    Zhang, Huina
    Chen, Lifang
    Zhao, Peng
    Zhao, Jing
    Fu, Guangming
    Xing, Xiaoming
    Li, Yujun
    Wang, Chengqin
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (02) : 313 - 323
  • [28] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Zhaoxu Chen
    Huiqing Jia
    Huina Zhang
    Lifang Chen
    Peng Zhao
    Jing Zhao
    Guangming Fu
    Xiaoming Xing
    Yujun Li
    Chengqin Wang
    [J]. Breast Cancer Research and Treatment, 2023, 202 : 313 - 323
  • [29] A pilot study of pertuzumab, trastuzumab and eribulin for patients with advanced HER2 positive breast cancer
    Ishihara, M.
    Tamaru, S.
    Oda, H.
    Yamashita, Y.
    Tono, Y.
    Mizuno, T.
    Katayama, N.
    [J]. CANCER RESEARCH, 2016, 76
  • [30] Cardiotoxicity of trastuzumab adjuvant treatment in positive HER2 breast cancer
    Piotrowski, G.
    Gawor, R.
    Potemski, P.
    Gawor, Z.
    [J]. EUROPEAN HEART JOURNAL, 2013, 34 : 831 - 832
12345